Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mitaplatin
- Development stage
- Unknown
- Lead developer
- Jiangsu Aosaikang Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intra-arterial
01
Overview
Mitaplatin (ASK0912) is a platinum(IV) prodrug designed to co-deliver cisplatin and dichloroacetate (DCA) to cancer cells. Developed by Jiangsu Aosaikang Pharmaceutical, it aims to overcome platinum resistance and enhance efficacy by simultaneously targeting nuclear DNA and mitochondrial metabolism. Upon intracellular reduction, mitaplatin releases cisplatin, which induces DNA damage and apoptosis, and DCA, which inhibits pyruvate dehydrogenase kinase (PDK). Inhibition of PDK reverses the Warburg effect (aerobic glycolysis) in tumor cells, promoting mitochondrial oxidative phosphorylation and sensitizing cells to apoptosis. It has been primarily investigated in China for the treatment of unresectable hepatocellular carcinoma (HCC) as part of transarterial chemoembolization (TACE) regimens.
- Other names
- 米塔铂
02
Targets
PDK (Pyruvate dehydrogenase kinase isoform 1)DNA
Beyond the preview
Go deeper on mitaplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mitaplatin.